Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nanosomal tacrolimus - Intas Pharmaceuticals/Jina Pharmaceuticals

Next Previous
X
Search
Drug Profile

Nanosomal tacrolimus - Intas Pharmaceuticals/Jina Pharmaceuticals

Alternative Names: Nanosomal tacrolimus; Tacrolimus liposomal; Tacrolimus-Lipid Suspension

Latest Information Update: 07 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antiglaucomas; Antipsoriatics; Antirheumatics; Eye disorder therapies; Lactones; Macrolides; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Transplant rejection
  • Phase III Atopic dermatitis
  • Phase II Rheumatoid arthritis
  • No development reported Lichen planus

Most Recent Events

  • 07 Sep 2022 No development reported - Phase-III for Lichen planus in India (Topical)
  • 22 Jul 2022 Phase-III clinical trials in Lichen planus (Topical) development is ongoing in India
  • 27 Sep 2019 Intas Pharmaceuticals plans a phase III trial for Rheumatoid arthritis (Treatment experienced) in India (CTRI2019-05-018873)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top